These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 31994229)

  • 1. Real-world efficacy and safety of interleukin-17 inhibitors for psoriasis: A single-center experience.
    Ohata C; Ohyama B; Katayama E; Nakama T
    J Dermatol; 2020 Apr; 47(4):405-408. PubMed ID: 31994229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study.
    Lebwohl MG; Blauvelt A; Menter A; Papp KA; Guenthner S; Pillai R; Israel RJ; Jacobson A
    Am J Clin Dermatol; 2019 Dec; 20(6):863-871. PubMed ID: 31493163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-interleukin-17 therapies for moderate/severe psoriasis in clinical practice: effectiveness, safety and association with clinical patient factors.
    García-Martín E; Romero-Jiménez RM; Baniandrés-Rodríguez O; Escudero-Vilaplana V; Benedí-González J; de Los Ríos Luna PM; Herranz-Alonso A; Sanjurjo-Sáez M
    Eur J Hosp Pharm; 2024 Aug; 31(5):409-415. PubMed ID: 37094886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience.
    Conti A; Peccerillo F; Amerio P; Balato A; Bardazzi F; Bianchi L; Burlando M; Cannavò SP; Chiricozzi A; Dapavo P; De Simone C; Fargnoli MC; Gambardella A; Gisondi P; Malagoli P; Malara G; Mugheddu C; Offidani AM; Piaserico S; Prignano F; Stingeni L; Pellacani G
    Br J Dermatol; 2019 Jun; 180(6):1547-1548. PubMed ID: 30578668
    [No Abstract]   [Full Text] [Related]  

  • 5. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis.
    Gordon KB; Leonardi CL; Lebwohl M; Blauvelt A; Cameron GS; Braun D; Erickson J; Heffernan M
    J Am Acad Dermatol; 2014 Dec; 71(6):1176-82. PubMed ID: 25242558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.
    Bilal J; Berlinberg A; Bhattacharjee S; Trost J; Riaz IB; Kurtzman DJB
    J Dermatolog Treat; 2018 Sep; 29(6):569-578. PubMed ID: 29532693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ixekizumab Effectiveness and Safety in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Multicenter, Retrospective Observational Study.
    Chiricozzi A; Burlando M; Caldarola G; Conti A; Damiani G; De Simone C; Dini V; Malagoli P; Peccerillo F; Potenza C; Scala E; Skroza N; Balato A
    Am J Clin Dermatol; 2020 Jun; 21(3):441-447. PubMed ID: 31786732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study.
    Gasslitter I; Kirsten N; Augustin M; Torz K; Mrowietz U; Eyerich K; Puig L; Hoetzenecker W; Schütz-Bergmayr M; Weger W; Wolf P; Reider N; Ratzinger G; Papageorgiou K; Meier TO; Maul JT; Anzengruber F; Navarini AA
    Arch Dermatol Res; 2019 Jul; 311(5):421-424. PubMed ID: 30879102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world risk of new-onset inflammatory bowel disease among patients with psoriasis exposed to interleukin 17 inhibitors.
    Wright S; Alloo A; Strunk A; Garg A
    J Am Acad Dermatol; 2020 Aug; 83(2):382-387. PubMed ID: 32289401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-17A Inhibitor Switching - Efficacy of Ixekizumab Following Secukinumab Failure. A Single-center Experience.
    Sherman S; Solomon Cohen E; Amitay-Laish I; Hodak E; Pavlovsky L
    Acta Derm Venereol; 2019 Jul; 99(9):769-773. PubMed ID: 31017250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: The Corrona Psoriasis Registry.
    Lockshin B; Cronin A; Harrison RW; McLean RR; Anatale-Tardiff L; Burge R; Zhu B; Malatestinic WN; Atiya B; Murage MJ; Gallo G; Strober B; Van Voorhees A
    Dermatol Ther; 2021 Mar; 34(2):e14808. PubMed ID: 33491259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of IL-17 inhibitors for psoriasis.
    Amin M; Darji K; No DJ; Bhutani T; Wu JJ
    J Dermatolog Treat; 2018 Jun; 29(4):347-352. PubMed ID: 29058501
    [No Abstract]   [Full Text] [Related]  

  • 13. Real-world effectiveness and safety of bimekizumab in Japanese patients with psoriasis: A single-center retrospective study.
    Hagino T; Saeki H; Fujimoto E; Kanda N
    J Dermatol; 2024 May; 51(5):649-658. PubMed ID: 38482898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI; Hooft L
    Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).
    Saeki H; Nakagawa H; Nakajo K; Ishii T; Morisaki Y; Aoki T; Cameron GS; Osuntokun OO;
    J Dermatol; 2017 Apr; 44(4):355-362. PubMed ID: 27726163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug survival, effectiveness, and safety of brodalumab for moderate-to-severe psoriasis up to 3 years.
    Mastorino L; Dapavo P; Burzi L; Rosset F; Giunipero di Corteranzo I; Leo F; Verrone A; Stroppiana E; Ortoncelli M; Ribero S; Quaglino P
    Int J Dermatol; 2024 Jul; 63(7):922-928. PubMed ID: 38284277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-17 inhibitors for psoriasis.
    Paek SY; Frieder J; Kivelevitch D; Menter MA
    Semin Cutan Med Surg; 2018 Sep; 37(3):148-157. PubMed ID: 30215631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis.
    AbuHilal M; Walsh S; Shear N
    J Cutan Med Surg; 2016 Nov; 20(6):509-516. PubMed ID: 27207350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Therapeutic Approaches and Targets for Treatment of Psoriasis.
    Radi G; Campanati A; Diotallevi F; Bianchelli T; Offidani A
    Curr Pharm Biotechnol; 2021; 22(1):7-31. PubMed ID: 32598253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ixekizumab for the treatment of psoriasis: up-to-date.
    Craig S; Warren RB
    Expert Opin Biol Ther; 2020 Jun; 20(6):549-557. PubMed ID: 32050819
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.